Products
By Team
Sales
Multithread effectively and personalize outreach to convert deals faster
Social Media Marketing
Elevate social presence and drive business growth from social media
RevOps
Identify and prioritize high-intent leads, and improve sales effectiveness
Events & Field Marketing
Find and connect with ICP attendees, and improve event outcomes
Resources
.png)
.png)
arvinas
Overview
Arvinas, a clinical-stage biopharmaceutical company, is a pioneering force in the field of targeted protein degradation, focusing on the development of novel therapies using its proprietary PROTAC® technology. Operating within the highly competitive biotechnology sector, Arvinas is positioned as an innovator, aiming to revolutionize the treatment of cancers and other difficult-to-treat diseases by selectively eliminating disease-causing proteins. With strategic partnerships, including collaborations with pharmaceutical giants like Pfizer and Bayer, Arvinas is advancing its pipeline of PROTAC®-based drug candidates through clinical trials, targeting significant unmet medical needs and seeking to establish a leadership position in this emerging therapeutic modality.
arvinas's headcount breakdown by department
| Department | HeadCount |
|---|---|
Administrative | 13 |
Consulting | 2 |
Service | 0 |
Design | 0 |
Education | 0 |
Arvinas' departmental distribution reflects a strong emphasis on research and development, indicative of a clinical-stage biotechnology company deeply invested in scientific innovation. The substantial Research team (125 employees) and significant Medical Affairs presence (46 employees) are crucial for driving drug discovery, preclinical studies, and clinical trial execution. The supporting Operations team (22 employees) ensures seamless execution of R&D activities and clinical operations. The relatively smaller teams in areas like HR, Finance, Legal, and General Management indicate a streamlined administrative structure designed to support the core scientific and clinical functions. The very small Sales and Marketing teams suggest a current business strategy focused on advancing clinical programs and securing strategic partnerships, with commercialization efforts likely to be significantly scaled up as the company approaches potential product launches. The sizable 'Other' department (68 employees) might encompass roles supporting specific research programs, early-stage development activities, or specialized technical functions within the PROTAC® platform. This structure aligns with the typical profile of a biotech company heavily focused on R&D and clinical development, prioritizing scientific advancements and strategic collaborations over immediate commercialization.
arvinas's employees by locations
Employee Count by Country
Total: 344 employees
Arvinas exhibits a predominantly domestic workforce, with a strong concentration of employees in the United States (339 employees). This reflects the company's origins as a US-based biotech and indicates that its core operations, including research and development, clinical operations, and corporate management, are primarily located within the US. The limited presence in the United Kingdom (5 employees) suggests a strategic footprint to support European clinical trials, facilitate collaborations with UK-based research institutions, or potentially access European talent. This concentrated geographic strategy aligns with a US-centric clinical development pathway and may also reflect the location of key strategic partnerships and funding sources. As Arvinas progresses towards potential commercialization of its PROTAC®-based therapies, a more globally distributed workforce may become necessary to support international regulatory submissions, manufacturing, and commercialization efforts across key markets in Europe and Asia.
Want to stay ahead of arvinas's org changes?
Get alerts when hiring spikes or teams shift focus
Track changes vs. competitors
Spot warm GTM signals early